Fig. 3From: NKX2–1 expression as a prognostic marker in early-stage non-small-cell lung cancerKaplan Meier analysis of overall survival according to NKX2–1 expression levels in patients harboring neither TP53 nor KRAS mutations in a the entire cohort and b patients with stage I diseaseBack to article page